医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ReproCELL Announced: Regarding the Synergistic Effects of Our Complete Subsidiary Acquisition of Biopta Limited

2015年11月26日 PM10:00
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

ReproCELL, Inc. (JASDAQ: 4978) announces that at a director meeting held on November 24th, 2015, the complete subsidiary acquisition of English company Biopta Limited (hereafter referred to as Biopta) was decided upon.

Our company group has up to now been involved in the global development of research reagent products and cell products through its use of cutting edge techniques involving human iPS cells, and continues healthy business expansion in said market, which is showing remarkable development.

Biopta, the company purchased, offer a drug development support service targeted at the drug industry, and can boast to having dealings with 8 of the top 10 mega pharma companies. The drug development support service offered by Biopta is an outsourcing business that, through human cell activities, carries out research and tests for exploratory research and preclinical testing, which up until now were carried out using animal testing. This field’s potential market size is expected to rise to ¥1,750,000,000,000, and is attracting a lot of attention. The biggest strength of the company is its ability to use the network of medical institutions that it owns across England and America to acquire very fresh human tissue and internal organs in a timely manner. From this abundant cell lineup, the company can pick up human tissue and internal organs requested at the preclinical trial stage of drug development, allowing it to offer an outsourced drug development support service that is desirable to individual clients.

Through this purchase, Biopta’s drug development support service joins the business lineup of our company group, allowing us to target pharmaceutical companies, covering both providing products and delegated research. Further, making use of the synergy of our company group’s global, cutting edge iPS cell cultivation technology and Biopta’s GLP certified equipment and its high level of service knowhow in using it, as a new part of our business we can start on the early stages of an unprecedented “preclinical test service business using iPS cells” and create a real competitive superiority.

For more information,visit: https://www.reprocell.com/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005046/en/

CONTACT

ReproCELL, Inc. (JASDAQ Company code: 4978)
Chikafumi Yokoyama,
+81-45-475-3887
PhD
info_en@reprocell.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Ra Medical Systems Receives Approval in China for Pharos Dermatology Laser
  • Cardiovascular Systems, Inc. Receives Approval for the Diamondback 360® Coronary Orbital Atherectomy System (OAS) Micro Crown in Japan
  • Gynesonics Names James Sparks Vice President of Manufacturing
  • Takeda Announces Ricardo Marek as New President of Emerging Markets Business Unit
  • Takeda’s Dengue Vaccine Candidate Elicited Broad Immune Responses in Children and Adolescents Living in Dengue-Endemic Areas; Interim Phase 2 Analysis Published in The Lancet Infectious Diseases